Marinus Pharmaceuticals Inc. MRNS
Last Post: 04/22/2024 10:26:00 AM
Board Marks: 1
Posts Today: 0
Board Views Today: 47
Company Website: http://www.marinuspharma.com/
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) Stock Message Board
Post
Subject
Author
Posted On
| 5 | MRNS 7.50 Marinus Pharmaceuticals Inc $MRNS stock | clayton | 12/02/2014 10:24:17 AM |
| 4 | MRNS Stock year to date has changed -6.25% | Jake13 | 12/02/2014 2:21:16 AM |
| 3 | MRNS 7.50 Marinus Pharmaceuticals Inc Stock | chartguy89 | 12/02/2014 2:09:29 AM |
| 2 | MRNS 7.10 Marinus Pharmaceuticals Inc $MRNS stock | clayton | 11/24/2014 3:32:50 PM |
| 1 | MRNS 6.79 Marinus Pharmaceuticals Inc $MRNS added | clayton | 11/20/2014 11:14:34 AM |